<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">RSX</journal-id>
<journal-id journal-id-type="hwp">sprsx</journal-id>
<journal-id journal-id-type="nlm-ta">Reprod Sci</journal-id>
<journal-title>Reproductive Sciences</journal-title>
<issn pub-type="ppub">1933-7191</issn>
<issn pub-type="epub">1933-7205</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1933719112459244</article-id>
<article-id pub-id-type="publisher-id">10.1177_1933719112459244</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Extrapituitary Effects of GnRH Antagonists and Their Potential Clinical Implications: A Narrated Review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tan</surname>
<given-names>Orkun</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1933719112459244">1</xref>
<xref ref-type="corresp" rid="corresp1-1933719112459244"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carr</surname>
<given-names>Bruce R.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1933719112459244">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beshay</surname>
<given-names>Victor E.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1933719112459244">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bukulmez</surname>
<given-names>Orhan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1933719112459244">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1933719112459244">
<label>1</label>Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Texas Southwestern Medical Center, Dallas, TX, USA</aff>
<author-notes>
<corresp id="corresp1-1933719112459244">Orkun Tan, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Division of Reproductive Endocrinology and Infertility, 5323 Harry Hines Blvd. J6, Dallas, TX 75390, USA Email: <email>orkun.tan@utsouthwestern.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>20</volume>
<issue>1</issue>
<fpage>16</fpage>
<lpage>25</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society for Gynecologic Investigation</copyright-holder>
</permissions>
<abstract>
<p>Potential roles of gonadotropin-releasing hormone (GnRH) antagonists on GnRH/GnRH receptor systems and their effects on the extrapituitary tissues are largely elusive. In this narrated review, we summarized the systemic effects of GnRH antagonists on ovary, endometrium, embryo implantation, placental development, fetal teratogenicity, reproductive tissue cancer cells, and heart while briefly reviewing the GnRH and GnRH receptor system. GnRH antagonists may have direct effects on ovarian granulosa cells. Data are conflicting regarding their effects on endometrial receptivity. The GnRH antagonists may potentially have detrimental effect on early placentation by decreasing the invasive ability of cytotrophoblasts if the exposure to them occurs during early pregnancy. The GnRH antagonists were not found to increase the rates of congenital malformations. Comparative clinical data are required to explore their systemic effects on various extrapituitary tissues such as on cardiac function in the long term as well as their potential use in other human cancers that express GnRH receptors.</p>
</abstract>
<kwd-group>
<kwd>GnRH types</kwd>
<kwd>GnRH receptors</kwd>
<kwd>GnRH antagonist</kwd>
<kwd>implantation</kwd>
<kwd>endometrium</kwd>
<kwd>ovary</kwd>
<kwd>heart</kwd>
<kwd>controlled ovarian stimulation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1933719112459244">
<title>Introduction</title>
<p>Gonadotropin-releasing hormone type I (GnRH-I) is the classic hypothalamic hormone that controls the synthesis and secretion of gonadotropins in the pituitary.<sup><xref ref-type="bibr" rid="bibr1-1933719112459244">1</xref></sup> The GnRH-I is also present in extrapituitary tissues such as endometrium,<sup><xref ref-type="bibr" rid="bibr2-1933719112459244">2</xref></sup> myometrium,<sup><xref ref-type="bibr" rid="bibr3-1933719112459244">3</xref></sup> fallopian tube epithelium,<sup><xref ref-type="bibr" rid="bibr4-1933719112459244">4</xref></sup> ovarian surface epithelial (OSE) cells,<sup><xref ref-type="bibr" rid="bibr5-1933719112459244">5</xref></sup> ovarian granulosa lutein (GL) cells,<sup><xref ref-type="bibr" rid="bibr6-1933719112459244">6</xref></sup> preimplantation embryo,<sup><xref ref-type="bibr" rid="bibr7-1933719112459244">7</xref></sup> and placenta<sup><xref ref-type="bibr" rid="bibr8-1933719112459244">8</xref></sup> (<xref ref-type="table" rid="table1-1933719112459244">Table 1</xref>).</p>
<table-wrap id="table1-1933719112459244" position="float">
<label>Table 1.</label>
<caption>
<p>Localization of Different GnRH Types in Humans</p>
</caption>
<graphic alternate-form-of="table1-1933719112459244" xlink:href="10.1177_1933719112459244-table1.tif"/>
<table>
<thead>
<tr>
<th>GnRH Type I</th>
<th>GnRH Type II</th>
<th>GnRH Type III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypothalamus</td>
<td>Hypothalamus</td>
<td>Hypothalamus</td>
</tr>
<tr>
<td>Endometrium</td>
<td>Endometrium</td>
<td>Midbrain</td>
</tr>
<tr>
<td>Fallopian tube epithelium</td>
<td>Kidney</td>
<td/>
</tr>
<tr>
<td>Ovarian GL cells</td>
<td>Ovarian GL cells</td>
<td/>
</tr>
<tr>
<td>Ovarian surface epithelium</td>
<td>Ovarian surface epithelium</td>
<td/>
</tr>
<tr>
<td>Ovarian carcinoma</td>
<td>Ovarian carcinoma</td>
<td/>
</tr>
<tr>
<td>Placenta</td>
<td>Placenta</td>
<td/>
</tr>
<tr>
<td>Breast tissue</td>
<td>Prostate</td>
<td/>
</tr>
<tr>
<td>Breast cancer</td>
<td>Breast tissue</td>
<td/>
</tr>
<tr>
<td>Preimplantation embryo<sup>a</sup>
</td>
<td>Breast cancer</td>
<td/>
</tr>
<tr>
<td/>
<td>Bone marrow</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1933719112459244">
<p>Expression of GnRH-I has been demonstrated in hypothalamic and extrahypothalamic human tissues. The GnRH-II is expressed at significantly higher levels outside the brain. The GnRH-III containing neurons are demonstrated in the hypothalamus and midbrain of humans.</p>
</fn>
<fn id="table-fn5-1933719112459244">
<p>
<sup>a</sup>Present in blastomeres as well as in the trophoectoderm and inner cell mass of the blastocyst.</p>
</fn>
<fn id="table-fn6-1933719112459244">
<p>Abbreviations:  GL, granulosa lutein; GnRH, gonadotropin-releasing hormone.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>A gene-encoding GnRH-II was also cloned from human brain tissue.<sup><xref ref-type="bibr" rid="bibr9-1933719112459244">9</xref></sup> The human <italic>GnRH-I</italic> gene is longer than the <italic>GnRH-II</italic> gene because introns 2 and 3 of the <italic>GnRH-I</italic> gene are larger<sup><xref ref-type="bibr" rid="bibr9-1933719112459244">9</xref></sup> (see <xref ref-type="fig" rid="fig1-1933719112459244">Figure 1</xref> for comparison of <italic>GnRH-I</italic> and  <italic>GnRH-II</italic> genes in humans). In humans, <italic>GnRH-II</italic> is expressed in extrahypothalamic tissues such as human endometrium,<sup><xref ref-type="bibr" rid="bibr10-1933719112459244">10</xref></sup> breast tissue,<sup><xref ref-type="bibr" rid="bibr11-1933719112459244">11</xref></sup> ovarian GL,<sup><xref ref-type="bibr" rid="bibr12-1933719112459244">12</xref>,<xref ref-type="bibr" rid="bibr13-1933719112459244">13</xref></sup> and ovarian surface epithelial (OSE) cells<sup><xref ref-type="bibr" rid="bibr12-1933719112459244">12</xref></sup> (<xref ref-type="table" rid="table1-1933719112459244">Table 1</xref>). Although GnRH-IIR is present in the human tissues, to date, a fully functional GnRH-II and GnRH-IIR complex has not been shown due to a frameshift mutation in GnRH-IIR leading to the gene disruption.<sup><xref ref-type="bibr" rid="bibr14-1933719112459244">14</xref></sup> In human midbrain and hypothalamus, GnRH-III containing neurons were also identified by immunohistochemistry<sup><xref ref-type="bibr" rid="bibr15-1933719112459244">15</xref></sup> (<xref ref-type="table" rid="table1-1933719112459244">Table 1</xref>). Similar to GnRH-I and -II, GnRH-IR (Figure <xref ref-type="fig" rid="fig2-1933719112459244">2</xref>) and GnRH-IIR (Figure <xref ref-type="fig" rid="fig3-1933719112459244">3</xref>) were detected in pituitary<sup><xref ref-type="bibr" rid="bibr16-1933719112459244">16</xref>,<xref ref-type="bibr" rid="bibr17-1933719112459244">17</xref></sup> and extrapituitary human tissues.<sup><xref ref-type="bibr" rid="bibr18-1933719112459244">18</xref><xref ref-type="bibr" rid="bibr19-1933719112459244"/>–<xref ref-type="bibr" rid="bibr20-1933719112459244">20</xref></sup></p>
<fig id="fig1-1933719112459244" position="float">
<label>Figure 1.</label>
<caption>
<p>The structure of <italic>GnRH-I</italic> and <italic>GnRH-II</italic> genes in humans.</p>
</caption>
<alt-text>Human GnRH-I gene is composed of 4 exons separated by 3 introns. The first exon consists of 61 base pairs. The second exon encodes the signal sequence, the GnRH decapeptide, and the first 11 GAP residues. The third exon encodes the next 32 GAP residues. The fourth exon contains the translation termination codon. The GnRH-II gene comprises 4 exons interrupted by 3 introns. The human GnRH-II gene (2.1 kb) is shorter than the GnRH-I gene (5 kb) because introns 2 and 3 of the latter are much larger. GnRH indicates gonadotropin-releasing hormone; GAP, GnRH-associated peptide.</alt-text>
<graphic xlink:href="10.1177_1933719112459244-fig1.tif"/>
</fig>
<fig id="fig2-1933719112459244" position="float">
<label>Figure 2.</label>
<caption>
<p>Expression of GnRH-I receptor in humans.</p>
</caption>
<alt-text>The GnRH-I receptor (-IR) is present in many human tissues. *Epithelial ovarian carcinoma and multiple ovarian cancer cell lines express GnRH-IR mRNA. **Human endometrial cancer and Ishikawa endometrial cancer cell lines express GnRH-IR mRNA. ***Breast carcinoma and MCF-7 breast cancer cells express GnRH-IR mRNA. GnRH indicates gonadotropin-releasing hormone; mRNA, messenger RNA.</alt-text>
<graphic xlink:href="10.1177_1933719112459244-fig2.tif"/>
</fig>
<fig id="fig3-1933719112459244" position="float">
<label>Figure 3.</label>
<caption>
<p>Expression of GnRH-II receptor in humans.</p>
</caption>
<alt-text>The GnRH-II receptor (GnRH-IIR) distribution is not concentrated in any organ system such as endocrine glands or reproductive tissues. The GnRH-IIR is detectable in ovary, breast, endometrium, gastrointestinal organs, and in mature human sperm. *Although present in certain tissues, functional GnRH-IIR transcript in human tissues is lacking. GnRH indicates gonadotropin releasing hormone.</alt-text>
<graphic xlink:href="10.1177_1933719112459244-fig3.tif"/>
</fig>
<p>To date, many GnRH analogues with different biological potencies have been developed for the treatment of various reproductive disorders.<sup><xref ref-type="bibr" rid="bibr21-1933719112459244">21</xref><xref ref-type="bibr" rid="bibr22-1933719112459244"/>–<xref ref-type="bibr" rid="bibr23-1933719112459244">23</xref></sup> The GnRH antagonists (GnRH-ants) are commonly used in in vitro fertilization cycles for pituitary suppression, however, they are also being used to treat various systematic disorders such as prostate cancer. Since the systemic effects of many available GnRH-ants on various extrapituitary tissues and the receptors (GnRH-IR or GnRH-IIR) with which they exert their effects are largely unknown, we found it timely to summarize the direct systemic effects of GnRH-ants on endometrium, implantation, ovary, breast tissue, prostate, and heart while briefly reviewing the GnRH and GnRH receptor system.</p>
</sec>
<sec id="section2-1933719112459244">
<title>Search Methods</title>
<p>All peer-reviewed journal articles published before June 2012 for each area discussed (role of GnRH-ants in ovary, endometrium, embryo implantation, pregnancy rates, placental development, fetal teratogenicity, cancer cells, and heart) were searched by PubMed, Medline, Cochrane database, and Scopus for a narrated literature review and the relevant findings were summarized. The search was limited to both prospective and retrospective studies that were published as full text in English only. The search was without temporal limits but mainly yielded publications between 1995 and 2012. Ninety-six percent of the studies described were performed during the past 12 years (2000-2012); more specifically, 4% of the studies were performed during the period from 1995 to 1999, 33% of the studies were performed during the period from 2000 to 2005, and 53% in the period from 2006 to June 2012.</p>
</sec>
<sec id="section3-1933719112459244">
<title>Gonadotropin-Releasing Hormone Antagonists</title>
<p>There are 4 GnRH-ants currently approved by the Food and Drug Administration (FDA).<sup><xref ref-type="bibr" rid="bibr24-1933719112459244">24</xref></sup> Ganirelix (Antagon, Ganirelix acetate; Merck, New Jersey) and Cetrorelix (Cetrotide; EMD Serono International S.A., Geneve, Switzerland) are commercially available for the prevention of premature LH surge during in vitro fertilization (IVF) cycles. Both Degarelix acetate (Firmagon; Ferring Pharmauceticals, Saint-Prex, Switzerland) and Abarelix (Plenaxis; Praecis Pharmaceuticals Inc, Waltham, Massachusetts) are the third-generation GnRH-ants, and they have been approved for the treatment of advanced stage prostatic cancer. Abarelix has been discontinued in the market.<sup><xref ref-type="bibr" rid="bibr24-1933719112459244">24</xref>,<xref ref-type="bibr" rid="bibr25-1933719112459244">25</xref></sup></p>
<p>Ozarelix and F-75998 are the fourth-generation GnRH-ants, and they are currently being utilized in experimental studies.<sup><xref ref-type="bibr" rid="bibr26-1933719112459244">26</xref>,<xref ref-type="bibr" rid="bibr27-1933719112459244">27</xref></sup> An orally active nonpeptide GnRH-ant, Elagolix, has been studied for the treatment of uterine fibroids, endometriosis, and benign prostatic hyperplasia.<sup><xref ref-type="bibr" rid="bibr24-1933719112459244">24</xref>,<xref ref-type="bibr" rid="bibr28-1933719112459244">28</xref>,<xref ref-type="bibr" rid="bibr29-1933719112459244">29</xref></sup> Elagolix is not yet FDA approved.<sup><xref ref-type="bibr" rid="bibr24-1933719112459244">24</xref></sup></p>
</sec>
<sec id="section4-1933719112459244">
<title>The Role of GnRH Antagonists in Ovary</title>
<p>Both GnRH-IR and GnRH-IIR have been identified in the ovary.<sup><xref ref-type="bibr" rid="bibr30-1933719112459244">30</xref></sup> Choi et al<sup><xref ref-type="bibr" rid="bibr31-1933719112459244">31</xref></sup> investigated the GnRH/GnRH-IR expression during the development of human ovarian follicle. They showed that GnRH-I, -II, and GnRH-IR immunoreactivity were not present in the primordial and early antral stage follicles. However, GnRH-I, -II, and GnRH-IR were expressed in the granulosa cell layer; whereas the theca internal layer was weakly positive. Significant GnRH-I, -II, and GnRH-IR immunoreactivity were also observed in granulose lutein cells in the corpus luteum.<sup><xref ref-type="bibr" rid="bibr31-1933719112459244">31</xref></sup></p>
<p>The common use of GnRH antagonists raised many questions regarding their potential role in ovarian function through GnRH receptors.<sup><xref ref-type="bibr" rid="bibr30-1933719112459244">30</xref></sup> Weiss et al demonstrated in vitro that ganirelix and cetrorelix do not affect the steroidogenesis in the ovary.<sup><xref ref-type="bibr" rid="bibr32-1933719112459244">32</xref></sup> Another in vitro study in human granulosa luteinized cell cultures showed similar results that is both leuprolide and cetrorelix did not affect ovarian steroidogenesis.<sup><xref ref-type="bibr" rid="bibr33-1933719112459244">33</xref></sup></p>
<p>However, in some studies, GnRH-ant has been shown to be associated with lower levels of estradiol on the day of human chorionic gonadotropin (hCG) administration.<sup><xref ref-type="bibr" rid="bibr34-1933719112459244">34</xref>,<xref ref-type="bibr" rid="bibr35-1933719112459244">35</xref></sup> If GnRH-ant has a suppressive effect on the ovary, it is unclear whether this effect is via suppression of aromatase and/or the central inhibitory effects of the GnRH-ants. Winkler et al showed that mRNA expressions of anti-Mullerian hormone (AMH), CYP19IIa (gonadal aromatase promoter), and steroidogenic factor 1 (SF-1) were decreased by GnRH-ant (cetrorelix) in human granulosa cells.<sup><xref ref-type="bibr" rid="bibr36-1933719112459244">36</xref></sup> Similarly Garcia-Velasco et al<sup><xref ref-type="bibr" rid="bibr35-1933719112459244">35</xref></sup> demonstrated decreased follicular fluid estradiol concentrations in patients treated with GnRH-ants than in those treated with GnRH agonist (GnRH-ag). Therefore, GnRH-ants could play a direct role in ovarian granulosa cells’ function besides their suppressive effects on pituitary gonadotropin release.<sup><xref ref-type="bibr" rid="bibr24-1933719112459244">24</xref>,<xref ref-type="bibr" rid="bibr36-1933719112459244">36</xref></sup> However, further studies are required to validate these results and explore other potential pathways.</p>
</sec>
<sec id="section5-1933719112459244">
<title>Gonadotropin-Releasing Hormone Antagonists and Their Role in Endometrium and Embryo Implantation</title>
<p>Gonadotropin-releasing hormone receptor is present during all the developmental stages of the embryo, suggesting that the embryo interacts with the maternal tubal epithelium and endometrium to stimulate endometrial receptivity and embryonic development.<sup><xref ref-type="bibr" rid="bibr4-1933719112459244">4</xref>,<xref ref-type="bibr" rid="bibr7-1933719112459244">7</xref></sup> It was debated whether the ovarian stimulation during an IVF cycle may negatively affect embryo implantation<sup><xref ref-type="bibr" rid="bibr37-1933719112459244">37</xref>,<xref ref-type="bibr" rid="bibr38-1933719112459244">38</xref></sup> since GnRH-I, GnRH-II, and the GnRH-IR are expressed in normal endometrium.<sup><xref ref-type="bibr" rid="bibr39-1933719112459244">39</xref></sup> The GnRH has been shown to modulate matrix metalloproteinases (MMPs) that play a role in endometrial remodeling and preparation of endometrium for implantation. Therefore, many questions were raised about the possible negative impacts of GnRH-ant on endometrial receptivity.<sup><xref ref-type="bibr" rid="bibr40-1933719112459244">40</xref><xref ref-type="bibr" rid="bibr41-1933719112459244"/><xref ref-type="bibr" rid="bibr42-1933719112459244"/>–<xref ref-type="bibr" rid="bibr43-1933719112459244">43</xref></sup></p>
<p>Bukulmez et al have previously shown that the sandwich GnRH-ant protocol resulted in lower clinical pregnancy rates compared with the GnRH-ag long protocol while the blastocyst progression and quality were comparable in the same study.<sup><xref ref-type="bibr" rid="bibr44-1933719112459244">44</xref></sup> The same authors then tried to determine whether higher cetrorelix levels in the GnRH-ant group, might be the cause of the difference in clinical pregnancy rates compared to the GnRH-ag long protocol group, however, they did not find any significant differences in serum cetrorelix concentrations between these 2 groups.<sup><xref ref-type="bibr" rid="bibr45-1933719112459244">45</xref></sup></p>
<p>Haouzi et al investigated the effects of GnRH-ag long protocols and GnRH-ant protocols on endometrial receptivity compared with natural cycles by analyzing the global gene expression profile during receptive stages of stimulated cycles.<sup><xref ref-type="bibr" rid="bibr46-1933719112459244">46</xref></sup> The number of downregulated genes common between stimulated and natural cycles was found to be similar when comparing GnRH-ag long protocol with the GnRH-ant protocol (10% in common with their natural cycle under the GnRH-ag protocol versus 7% under the GnRH-ant protocol). In the same study, of those genes upregulated during the receptive stage of the natural cycle, 5% matched those upregulated under GnRH-ag long protocol; whereas 36% were common to the profile resulting from the GnRH-ant protocol. In comparison to the endometrial receptivity under the GnRH-ag protocol, endometrial receptivity under the GnRH-ant protocol was more similar to that of the natural cycle.<sup><xref ref-type="bibr" rid="bibr46-1933719112459244">46</xref></sup></p>
<p>In addition, a prospective randomized study was performed to assist in clarifying the direct action of GnRH-ants on endometrial receptivity and pregnancy rates in oocyte donation cycles.<sup><xref ref-type="bibr" rid="bibr47-1933719112459244">47</xref></sup> Patients were randomly stratified either to receive a GnRH-ant concomitant to donor during their endometrial preparation with estradiol (group 1, n = 49) or to receive only estradiol for their endometrial preparation (group 2, n = 49). Pregnancy rate was 55.1% in group 1 and 59.1% in group 2. Pregnancy rates were similar between the 2 groups, indicating that GnRH-ant administration during the proliferative phase does not have any adverse effect on implantation and pregnancy rates in oocyte recipients.<sup><xref ref-type="bibr" rid="bibr47-1933719112459244">47</xref></sup> Although the study had limited power due to the small number of patients, these results appear to be reassuring regarding the direct effects of GnRH-ant on endometrial development and implantation. Similarly Martinez et al<sup><xref ref-type="bibr" rid="bibr48-1933719112459244">48</xref></sup> compared the pregnancy and implantation rates among premenopausal oocyte recipients synchronized by pituitary suppression with GnRH-ag or GnRH-ant and standard endometrium preparation with estrogen and progestin. They did not observe any difference in pregnancy rates comparing GnRH-ant group (52.4%) with the GnRH-ag group (56.1%).</p>
<p>Homeobox A10 (HOXA10) is one of the mediators of endometrial receptivity. Rackow et al assessed endometrial HOXA10 expression in GnRH-ant, GnRH-ag, and natural cycles in order to determine the effect of GnRH-ants on endometrial receptivity.<sup><xref ref-type="bibr" rid="bibr49-1933719112459244">49</xref></sup> Expression of HOXA10 was significantly decreased in endometrial stromal cells in GnRH-ant-treated cycles compared with GnRH-ag-treated cycles or natural cycle control participants. There was no significant difference in glandular cell HOXA10 expression among the 3 groups. It was concluded that the use of GnRH-ant may be associated with impaired HOXA10 expression in endometrial stromal cells and thus may affect endometrial receptivity.<sup><xref ref-type="bibr" rid="bibr49-1933719112459244">49</xref></sup></p>
<p>In conclusion, the data are conflicting regarding the impact of GnRH-ag long protocol and GnRH-ant protocols on endometrial receptivity, regardless of the approaches to assess endometrial receptivity itself.<sup><xref ref-type="bibr" rid="bibr47-1933719112459244">47</xref>,<xref ref-type="bibr" rid="bibr49-1933719112459244">49</xref><xref ref-type="bibr" rid="bibr50-1933719112459244"/>–<xref ref-type="bibr" rid="bibr51-1933719112459244">51</xref></sup> The differences between the results of the studies investigating the effects of GnRH analogues on endometrial receptivity could be due to (<italic>a</italic>) discrepancies in the timing of the endometrial biopsies, (<italic>b</italic>) differences in the controlled ovarian hyperstimulation (COH) protocols used, (<italic>c</italic>) differences in patient profiles, (<italic>d</italic>) inappropriate comparisons between samples, and (<italic>e</italic>) limited numbers of endometrial samples studied<sup><xref ref-type="bibr" rid="bibr46-1933719112459244">46</xref></sup> as well as the intracellular molecular interactions mediating the effects of GnRH-ags and GnRH-ants in human tissues.</p>
</sec>
<sec id="section6-1933719112459244">
<title>Gonadotropin-Releasing Hormone Antagonists and Pregnancy Rates</title>
<p>The results of studies published 10 years ago were inconsistent as to whether GnRH-ag long protocol is associated with higher clinical pregnancy rates compared to that of the GnRH-ant protocols during IVF cycles.<sup><xref ref-type="bibr" rid="bibr52-1933719112459244">52</xref><xref ref-type="bibr" rid="bibr53-1933719112459244"/><xref ref-type="bibr" rid="bibr54-1933719112459244"/>–<xref ref-type="bibr" rid="bibr55-1933719112459244">55</xref></sup> However, in a 2006 meta-analysis, there was no statistically significant difference in live birth rates comparing GnRH-ag with GnRH-ant protocols.<sup><xref ref-type="bibr" rid="bibr56-1933719112459244">56</xref></sup> In line with the 2006 meta-analysis,<sup><xref ref-type="bibr" rid="bibr56-1933719112459244">56</xref></sup> a 2011 meta-analysis also did not find any significant difference in ongoing pregnancy rates between the GnRH-ag and GnRH-ant protocols in oocyte donation cycles.<sup><xref ref-type="bibr" rid="bibr57-1933719112459244">57</xref></sup> A recently published update of 2011 Cochrane review included 45 trials addressing live birth or ongoing pregnancy rate in GnRH-ant and GnRH-ag protocols among women undergoing assisted reproduction.<sup><xref ref-type="bibr" rid="bibr58-1933719112459244">58</xref></sup> In 9 trials involving 1515 women, the average live birth rates with GnRH-ag and GnRH-ant treatment were 31.5% and 30%, respectively. However, live birth rates with GnRH-ag treatment were not statistically significant compared to those with GnRH-ant treatment. The relative risk of ovarian hyperstimulation syndrome (OHSS) with GnRH-ant treatment was 50% of that with GnRH-ag treatment (<italic>P</italic> = .003).<sup><xref ref-type="bibr" rid="bibr58-1933719112459244">58</xref></sup> Therefore, these findings may now justify a move away from the standard GnRH-ag long protocol to a GnRH-ant protocol for pituitary suppression.</p>
</sec>
<sec id="section7-1933719112459244">
<title>Gonadotropin-Releasing Hormone Antagonists: Placental Development and Fetal Teratogenicity</title>
<p>The GnRH-IR has also been identified in the cytotrophoblasts and syncytiotrophoblasts of the human placenta by in situ hybridization.<sup><xref ref-type="bibr" rid="bibr59-1933719112459244">59</xref>,<xref ref-type="bibr" rid="bibr60-1933719112459244">60</xref></sup> Both GnRH-I and GnRH-II bind to the GnRH-I receptor to stimulate the production and secretion of Beta-human chorionic gonadotropin (β-hcg). Placental GnRH-IR expression peaks at around 9 weeks of gestation, which is parallel to the peak of hcg.<sup><xref ref-type="bibr" rid="bibr59-1933719112459244">59</xref></sup> The MMPs are present in human placental trophoblasts and they are one of the key mediators of trophoblast cell invasion and extracellular matrix degradation. Recently, GnRH-I and GnRH-II have been found to regulate the expression of MMP-2 and -9 in human placental trophoblasts, and they also may play a role in trophoblast invasion through the activation of MMPs, plasminogen activators, and angiogenic factors.<sup><xref ref-type="bibr" rid="bibr61-1933719112459244">61</xref></sup> Therefore, GnRH-I and GnRH-II may work together in mediating the effects of different protease systems in placenta.<sup><xref ref-type="bibr" rid="bibr62-1933719112459244">62</xref>,<xref ref-type="bibr" rid="bibr63-1933719112459244">63</xref></sup> Liu et al studied how MMP-26 is regulated by GnRH-I and GnRH-II in human immortalized cytotrophoblast-like cell line (B6Tert-1).<sup><xref ref-type="bibr" rid="bibr64-1933719112459244">64</xref></sup> It was shown that GnRH-I and GnRH-II stimulated MMP-26 production by the primary cytotrophoblasts, and they stimulated the invasive ability of B6Tert-1 cells.<sup><xref ref-type="bibr" rid="bibr64-1933719112459244">64</xref></sup> Both GnRH-I and GnRH-II have been shown to affect the expression of matrix metalloproteases and plasminogen activators at the maternal–fetal interface and promote trophoblast invasion.<sup><xref ref-type="bibr" rid="bibr61-1933719112459244">61</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="bibr62-1933719112459244">62</xref></sup> These findings could raise the issue whether GnRH-ants may have any detrimental effect on early placentation by decreasing the invasive ability of cytotrophoblasts if the exposure to GnRH-ants occurs during the early pregnancy.</p>
<p>It has been debated whether GnRH-ants have any teratogenic potential on the early embryo<sup><xref ref-type="bibr" rid="bibr24-1933719112459244">24</xref></sup> since GnRH-I has been shown to be present in trophoectoderm and inner cell mass of the blastocyst.<sup><xref ref-type="bibr" rid="bibr65-1933719112459244">65</xref></sup> In a rat study, the effects of cetrorelix on early implantation were investigated.<sup><xref ref-type="bibr" rid="bibr66-1933719112459244">66</xref></sup> This study showed that the administration of the cetrorelix at various doses (15, 75, and 150 μg/kg cetrorelix vs saline) in the early postimplantation period suppressed fetoplacental development, decreased embryo weight, delayed delivery, and caused serious fetal malformations. However, the applicability of these results to humans is questionable since cetrorelix was used at very high doses in that study. In clinical studies, GnRH-ants were not found to increase the rates of congenital malformations when used in IVF protocols.<sup><xref ref-type="bibr" rid="bibr67-1933719112459244">67</xref><xref ref-type="bibr" rid="bibr68-1933719112459244"/>–<xref ref-type="bibr" rid="bibr69-1933719112459244">69</xref></sup></p>
<p>In line with these previous human studies, obstetrical and neonatal data from 969 live born infants after GnRH-ant (ganirelix) treatment were compared with 963 live born infants after long GnRH-ag (buserelin) treatment.<sup><xref ref-type="bibr" rid="bibr70-1933719112459244">70</xref></sup> Incidence of major congenital malformations in fetuses with gestational age ≥26 weeks was 5.0% in the ganirelix group versus 5.4% in the GnRH-ag group. These findings suggest that GnRH-ant (ganirelix) use during controlled ovarian stimulation is as safe as traditional GnRH-ag protocol (buserelin).<sup><xref ref-type="bibr" rid="bibr70-1933719112459244">70</xref></sup> Kyrou et al investigated whether there is any relationship between the proportion of chromosomally abnormal blastomeres and the type of pituitary suppression used in controlled ovarian stimulation cycles.<sup><xref ref-type="bibr" rid="bibr71-1933719112459244">71</xref></sup> They did not find any statistical difference in the proportion of abnormal blastomeres in the chromosomes when comparing GnRH-ag with the GnRH-ant protocol.<sup><xref ref-type="bibr" rid="bibr71-1933719112459244">71</xref></sup></p>
<p>In view of the current evidence, treatment with the GnRH-ants during controlled ovarian stimulation cycles is considered as safe as traditional GnRH-ags regarding the risk of congenital malformations.</p>
</sec>
<sec id="section8-1933719112459244">
<title>The Effects of GnRH Antagonists on Reproductive Tissue Cancer Cells</title>
<p>The antiproliferative and apoptotic effects of GnRH-ants on reproductive tissue cancer cells have been a recent area of interest.<sup><xref ref-type="bibr" rid="bibr26-1933719112459244">26</xref>,<xref ref-type="bibr" rid="bibr72-1933719112459244">72</xref><xref ref-type="bibr" rid="bibr73-1933719112459244"/><xref ref-type="bibr" rid="bibr74-1933719112459244"/><xref ref-type="bibr" rid="bibr75-1933719112459244"/>–<xref ref-type="bibr" rid="bibr76-1933719112459244">76</xref></sup> The majority of human cancer cells such as endometrium, ovary, breast, and prostate cancer express receptors for GnRH.<sup><xref ref-type="bibr" rid="bibr73-1933719112459244">73</xref><xref ref-type="bibr" rid="bibr74-1933719112459244"/>–<xref ref-type="bibr" rid="bibr75-1933719112459244">75</xref></sup> The role of GnRH-ants in preventing proliferative and invasive capabilities of these cancer cells has been extensively studied in vitro.</p>
<p>For example, GnRH-ant (MI-1544) showed an antiproliferative effect in human breast cancer cell lines (MCF-7 and MDA-MB-231).<sup><xref ref-type="bibr" rid="bibr77-1933719112459244">77</xref></sup> In androgen-independent prostate cancer cell lines, GnRH-ant (cetrorelix) has also been shown to inhibit proliferation and invasive capabilities of these cell lines.<sup><xref ref-type="bibr" rid="bibr72-1933719112459244">72</xref></sup> Similarly, a fourth-generation GnRH-ant (ozarelix) showed antiproliferative effects in androgen receptor negative prostate cancer cell lines and produced an accumulation of cells in G2/M cell cycle phase.<sup><xref ref-type="bibr" rid="bibr26-1933719112459244">26</xref></sup> Maudsley et al showed that selective GnRH-ants (135-18 and 135-25) exert potent antiproliferative effects on JEG-3 choriocarcinoma and benign prostate hyperplasia cells that express type I GnRH receptor. In that study, it was concluded that the ability of GnRH receptor antagonists to exert an antiproliferative effect on reproductive tumors may be dependent on ligand-selective activation of the G-alpha(i)-coupled form of the type I GnRH receptor.<sup><xref ref-type="bibr" rid="bibr73-1933719112459244">73</xref></sup> However, another study showed that although GnRH-ant cetrorelix similarly showed antiproliferative effects on endometrial and ovarian cancer cells, these effects were not mediated through type I GnRH receptor.<sup><xref ref-type="bibr" rid="bibr74-1933719112459244">74</xref></sup></p>
<p>The effects of GnRH-ants on antiproliferation and apoptosis in some cancer cell lines (ovary, endometrium, prostate) are very different from their effects on gonadotropin secretion. Ligand-induced selective signaling theory was in fact suggested from experiments in cancer cell lines. There are over 20 Gα proteins classified in 4 families: Gαq/11 phospholipase C, Gαs, Gαi, and Ga12/13 small GTPases.<sup><xref ref-type="bibr" rid="bibr78-1933719112459244">78</xref></sup> The GnRH-ants may antagonize Gαq but may act as full agonists in inhibiting cell growth through Gαi. The GnRH-ants may induce different G proteins or may influence various intracellular pathways including small molecule GTPases or RhoA, disrupting membrane assembly, spindle function, and cytoskeleton by affecting receptor configuration in GnRHR-I, since GnRHR-II may not be functional in humans (<xref ref-type="fig" rid="fig4-1933719112459244">Figure 4</xref>).<sup><xref ref-type="bibr" rid="bibr79-1933719112459244">79</xref></sup></p>
<fig id="fig4-1933719112459244" position="float">
<label>Figure 4.</label>
<caption>
<p>Intracellular signaling mechanisms of GnRH-l/GnRH-IR system. The GnRH-I acts primarily via Gq/11 protein to stimulate phospholipase C, with consequent mobilization of Ca<sup>2+</sup>. The GnRH-I also activates phospholipase A2, thus releasing arachidonic acid as well as phospholipase D. It also activates protein kinase C isozymes, extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK), and mitogen-activated protein kinase (MAPK) cascades which, together with Ca<sup>2+</sup>/calmodulin and its effectors, control gonadotropin synthesis. *Gq/11 protein belongs to G-protein subfamily. GnRH-IR indicates gonadotropin releasing hormone I receptor; IP3, inositol 1, 4, 5-triphosphate; DAG, diacylglycerol; Ca<sup>2+</sup>, calcium; F-GnRH-II, functional GnRH-II. **Functional GnRH-II receptor in humans is lacking.</p>
</caption>
<graphic xlink:href="10.1177_1933719112459244-fig4.tif"/>
</fig>
<p>Although GnRH-ants may have antiproliferative and antimetastatic effects on certain cancer cells, well-designed randomized controlled clinical trials are needed to determine the efficacy and safety of GnRH-ants in the treatment of GnRH-receptor-positive human cancers.</p>
</sec>
<sec id="section9-1933719112459244">
<title>Gonadotropin-Releasing Hormone Antagonists and Heart</title>
<p>Both the GnRH receptor mRNA<sup><xref ref-type="bibr" rid="bibr80-1933719112459244">80</xref></sup> and immunoreactive receptor<sup><xref ref-type="bibr" rid="bibr81-1933719112459244">81</xref></sup> have been demonstrated in human heart, providing evidence for an evolutionarily conserved role for GnRH in the heart. Since heart has GnRH receptors, GnRH-ants may potentially affect heart in many different ways. First, we would like to briefly mention about the effects of GnRH-ag on heart with long-term use. The GnRH-ags are used therapeutically to chemically castrate men with prostate cancer. This treatment is accompanied by various side effects (hot flashes, weight gain, and decreased libido), and has recently been associated with an overtly increased cardiovascular risk, although this effect was ascribed to the loss of circulating testosterone.<sup><xref ref-type="bibr" rid="bibr82-1933719112459244">82</xref></sup> However, some epidemiological studies have provided evidence of a significant increase in the prevalence of coronary heart disease, myocardial infarction, and sudden cardiac death in patients receiving GnRH-ag treatment compared to untreated and castrated men,<sup><xref ref-type="bibr" rid="bibr83-1933719112459244">83</xref>,<xref ref-type="bibr" rid="bibr84-1933719112459244">84</xref></sup> resulting in an FDA warning. In addition, oral antiandrogen monotherapy is not associated with negative cardiac outcomes,<sup><xref ref-type="bibr" rid="bibr85-1933719112459244">85</xref></sup> favoring the hypothesis that the GnRH-ags per se, rather than the loss of androgenic effects, are directly responsible for the negative health outcome.<sup><xref ref-type="bibr" rid="bibr86-1933719112459244">86</xref></sup></p>
<p>Because GnRH-ag treatment is associated with increased coronary heart disease and myocardial infarction, a recent study investigated the impact of GnRH on cardiomyocyte contractility.<sup><xref ref-type="bibr" rid="bibr86-1933719112459244">86</xref></sup> The GnRH had positive cardiomyocyte contractile effects via a GnRH receptor/phosphokinase A-dependent (PKA) mechanism in mice. The GnRH-induced cardiomyocyte mechanical responses were abolished or significantly attenuated by cetrorelix and PKA inhibitor (H89), suggesting an involvement of GnRH receptor and PKA in the GnRH-elicited cardiomyocyte contractile responses in mice. If present in the human heart, GnRH-ants may theoretically compromise cardiac contractile properties via inhibition of GnRH receptor/PKA-dependent pathway, leading to serious cardiac side effects.</p>
<p>In line with the above-mentioned hypothesis, a study in 2011 investigated the association of baseline cardiovascular disease risk profile, dosing regimen, and treatment duration with the incidence of cardiovascular disease events during androgen-deprivation therapy with degarelix in patients with prostate cancer.<sup><xref ref-type="bibr" rid="bibr87-1933719112459244">87</xref></sup> Cardiovascular event rates were similar before and after degarelix treatment in the total population (5.5 vs 6.1 of 100 person-years, <italic>P</italic> = .45) and in men without cardiovascular disease (5.6 vs 4.3 of 100 person-years, <italic>P</italic> = .11). In contrast, event rates appeared to be higher after degarelix treatment in men with cardiovascular disease at baseline (5.3-10.5 events per 100 person-years, <italic>P</italic> = .0013).<sup><xref ref-type="bibr" rid="bibr87-1933719112459244">87</xref></sup> The mechanisms by which degarelix could increase the risk of cardiovascular events in this population is currently unknown,<sup><xref ref-type="bibr" rid="bibr87-1933719112459244">87</xref></sup> and the safety of degarelix and other GnRH-ants in other organ systems such as cardiovascular system needs to be determined by placebo-controlled randomized trials in order to fully determine the comparative safety of GnRH-ants.</p>
</sec>
<sec id="section10-1933719112459244">
<title>Conclusion and Future Perspective</title>
<p>Both peptide (ganirelix, cetrorelix, antarelix, abarelix, iturelix, degarelix) and nonpeptide (elagolix, WAY-207024, TAK-013) GnRH-ants were developed, and they are currently utilized in gynecology, urology, oncology, and reproductive medicine for therapeutic or research purposes.<sup><xref ref-type="bibr" rid="bibr24-1933719112459244">24</xref></sup> Pregnancy and live birth rates are not statistically significant comparing GnRH-ant protocols with GnRH-ag long protocols, while the risk of ovarian hyperstimulation syndrome is lower with GnRH-ant protocols. The GnRH-ants are not associated with increased rate of congenital malformations. In addition to their use in the treatment of prostate cancer, GnRH-ants may also be used in the future for the treatment of other human cancers (such as ovary, endometrium, and breast) that express GnRH receptors.</p>
<p>The GnRH-ants have complex effects and they seem to be dependent on the cell type (<xref ref-type="table" rid="table2-1933719112459244">Table 2</xref>). The long-term effects of GnRH-ants on various organ systems are largely elusive. The current limited evidence suggests that GnRH-ants may impose differential effects on heart, which may have implications for their long-term use.<sup><xref ref-type="bibr" rid="bibr87-1933719112459244">87</xref></sup> The different effects of GnRH-ants in extrapituitary tissues may be due to the complex intracellular signaling pathways and receptor cross talks.<sup><xref ref-type="bibr" rid="bibr88-1933719112459244">88</xref></sup> Since many other peptide and nonpeptide GnRH-ants are currently being tested for their efficacy and safety, they will eventually find their way into clinical practice for long-term use. It may not be appropriate to predict GnRH-ants’ systemic side effects by extrapolating the data from the long-term GnRH-ag use or short-term use of peptide GnRH-ants in assisted reproduction technologies. Due to the various, tissue-specific receptor interactions, more detailed and comparative clinical data are needed to explore especially the long-term effects of GnRH-ants on various extrapituitary tissues when they are administered in a systemic fashion.</p>
<table-wrap id="table2-1933719112459244" position="float">
<label>Table 2.</label>
<caption>
<p>Summary of the Effects of GnRH Antagonists on Various Extrapituitary Tissues</p>
</caption>
<graphic alternate-form-of="table2-1933719112459244" xlink:href="10.1177_1933719112459244-table2.tif"/>
<table>
<thead>
<tr>
<th>Tissue</th>
<th>Presence of GnRH Type</th>
<th>Effect of GnRH Antagonist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovary</td>
<td>GnRH-l and -II</td>
<td>Debatable; no effect on ovarian steroidogenesis <sup><xref ref-type="bibr" rid="bibr32-1933719112459244">32</xref></sup>
<sup>,<xref ref-type="bibr" rid="bibr33-1933719112459244">33</xref></sup>; possible suppression of ovarian steroidogenesis <sup><xref ref-type="bibr" rid="bibr35-1933719112459244">35</xref></sup>
<sup>,<xref ref-type="bibr" rid="bibr36-1933719112459244">36</xref></sup>
</td>
</tr>
<tr>
<td>Endometrium/embryo implantation</td>
<td>GnRH-l and -II</td>
<td>Debatable; no effect on implantation<sup><xref ref-type="bibr" rid="bibr47-1933719112459244">47</xref></sup>
<sup>,<xref ref-type="bibr" rid="bibr48-1933719112459244">48</xref></sup>; possible interference with implantation due to decreased HOXA10 by Gn-antagonist treatment<sup><xref ref-type="bibr" rid="bibr49-1933719112459244">49</xref></sup>
</td>
</tr>
<tr>
<td>Placenta</td>
<td>GnRH-l and -II</td>
<td>Both GnRH-l and -II affect the expression of MMPs, and plasminogen activators and promote trophoblast invasion in placenta,<sup><xref ref-type="bibr" rid="bibr61-1933719112459244">61</xref></sup>
<sup>,<xref ref-type="bibr" rid="bibr62-1933719112459244">62</xref></sup> but the direct effects of GnRH antagonists on placenta are unknown.</td>
</tr>
<tr>
<td>Fetus</td>
<td>GnRH-la</td>
<td>No increased rate of fetal malformations when used in in vitro fertilization protocols<sup><xref ref-type="bibr" rid="bibr67-1933719112459244">67</xref></sup>
–<sup><xref ref-type="bibr" rid="bibr69-1933719112459244">69</xref></sup>
</td>
</tr>
<tr>
<td>Reproductive cancer cellsb</td>
<td>GnRH-l and GnRH-ll</td>
<td>Antiproliferative in human breast cancer cell lines (such as MCF-7)<sup><xref ref-type="bibr" rid="bibr77-1933719112459244">77</xref></sup> and androgen-independent prostate cancer cell lines (DU145 and PC3).<sup><xref ref-type="bibr" rid="bibr72-1933719112459244">72</xref></sup>; antiproliferative in benign prostate hyperplasia and JEG-3 choriocarcinoma cells.<sup><xref ref-type="bibr" rid="bibr73-1933719112459244">73</xref></sup>; antiproliferative in ovarian and endometrial cancer cells.<sup><xref ref-type="bibr" rid="bibr74-1933719112459244">74</xref></sup>
</td>
</tr>
<tr>
<td>Heart</td>
<td>GnRH-l and -II</td>
<td>No increased risk of cardiovascular events after GnRH-antagonist (degarelix) treatment in prostate cancer patients without cardiovascular disease, however, questionable increased risk of cardiovascular event rates in prostate cancer patients with cardiovascular disease at baseline.<sup><xref ref-type="bibr" rid="bibr87-1933719112459244">87</xref></sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1933719112459244">
<p>Abbreviation: GnRH, gonadotropin-releasing hormone.</p>
</fn>
</table-wrap-foot>
<table-wrap-foot>
<fn id="table-fn8-1933719112459244">
<p>
<sup>a</sup>Different GnRH types are present in various extrapituitary tissues. GnRH-I is present in preimplantation embryos as well as in the trophectoderm and inner cell mass of the blastocyst.</p>
</fn>
<fn id="table-fn9-1933719112459244">
<p>
<sup>b</sup>Such as endometrium, ovary, breast, and prostate cancer.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1933719112459244"><label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1933719112459244"><label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1933719112459244">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>YC</given-names>
</name>
<etal/>
</person-group> <article-title>Gonadotropin-releasing hormone positively regulates steroidogenesis via extracellular signal-regulated kinase in rat Leydig cells</article-title>. <source>Asian J Androl</source>. <year>2011</year>;<volume>13</volume>(<issue>3</issue>):<fpage>438</fpage>–<lpage>445</lpage>.</citation>
</ref>
<ref id="bibr2-1933719112459244">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JH</given-names>
</name>
<etal/>
</person-group> <article-title>Gonadotropin-releasing hormone agonist reduces aromatase cytochrome P450 and cyclooxygenase-2 in ovarian endometrioma and eutopic endometrium of patients with endometriosis</article-title>. <source>Gynecol Obstet Invest</source>. <year>2009</year>;<volume>68</volume>(<issue>2</issue>):<fpage>73</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr3-1933719112459244">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levens</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Chegini</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-beta through Smad and MAPK-mediated signalling</article-title>. <source>Mol Hum Reprod</source>. <year>2005</year>;<volume>11</volume>(<issue>7</issue>):<fpage>489</fpage>–<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr4-1933719112459244">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casan</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Raga</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bonilla-Musoles</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Polan</surname>
<given-names>ML</given-names>
</name>
</person-group>. <article-title>Human oviductal gonadotropin-releasing hormone: possible implications in fertilization, early embryonic development, and implantation</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2000</year>;<volume>85</volume>(<issue>4</issue>):<fpage>1377</fpage>–<lpage>1381</lpage>.</citation>
</ref>
<ref id="bibr5-1933719112459244">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Auersperg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>PC</given-names>
</name>
</person-group>. <article-title>Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells</article-title>. <source>Endocrinology</source>. <year>2001</year>;<volume>142</volume>(<issue>2</issue>):<fpage>580</fpage>–<lpage>588</lpage>.</citation>
</ref>
<ref id="bibr6-1933719112459244">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Krautmacher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Polack</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Diedrich</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ortmann</surname>
<given-names>O.</given-names>
</name>
</person-group> <article-title>Actions of GnRH antagonists on IGF-II, IGF-binding protein-2 and pregnancy-associated plasma protein-A in human granulosa-lutein cells</article-title>. <source>Eur J Endocrinol</source>. <year>2003</year>;<volume>149</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr7-1933719112459244">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jelodar</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Gholami</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jafarpour</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Effect of GnRH on guinea pig endometrium at preimplantation stage</article-title>. <source>Indian J Exp Biol</source>. <year>2007</year>;<volume>45</volume>(<issue>3</issue>):<fpage>242</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr8-1933719112459244">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chou</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Beristain</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>MacCalman</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>PC</given-names>
</name>
</person-group>. <article-title>Cellular localization of gonadotropin-releasing hormone (GnRH) I and GnRH II in first-trimester human placenta and decidua</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2004</year>;<volume>89</volume>(<issue>3</issue>):<fpage>1459</fpage>–<lpage>1466</lpage>.</citation>
</ref>
<ref id="bibr9-1933719112459244">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>White</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Eisen</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Kasten</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Fernald</surname>
<given-names>RD</given-names>
</name>
</person-group>. <article-title>Second gene for gonadotropin-releasing hormone in humans</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1998</year>;<volume>95</volume>(<issue>1</issue>):<fpage>305</fpage>–<lpage>309</lpage>.</citation>
</ref>
<ref id="bibr10-1933719112459244">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheon</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Parhar</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>IS</given-names>
</name>
</person-group>. <article-title>Expression of the second isoform of gonadotrophin-releasing hormone (GnRH-II) in human endometrium throughout the menstrual cycle</article-title>. <source>Mol Hum Reprod</source>. <year>2001</year>;<volume>7</volume>(<issue>5</issue>):<fpage>447</fpage>–<lpage>452</lpage>.</citation>
</ref>
<ref id="bibr11-1933719112459244">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fister</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gunthert</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Aicher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Paulini</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Emons</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Grundker</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax</article-title>. <source>Cancer Res</source>. <year>2009</year>;<volume>69</volume>(<issue>16</issue>):<fpage>6473</fpage>–<lpage>6481</lpage>.</citation>
</ref>
<ref id="bibr12-1933719112459244">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leung</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>XM</given-names>
</name>
</person-group>. <article-title>Multi-factorial role of GnRH-I and GnRH-II in the human ovary</article-title>. <source>Mol Cell Endocrinol</source>. <year>2003</year>;<volume>202</volume>(<issue>1-2</issue>):<fpage>145</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr13-1933719112459244">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Gilks</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Auersperg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>PC</given-names>
</name>
</person-group>. <article-title>Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2006</year>;<volume>91</volume>(<issue>11</issue>):<fpage>4562</fpage>–<lpage>4570</lpage>.</citation>
</ref>
<ref id="bibr14-1933719112459244">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stewart</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Millar</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Retention and silencing of prepro-GnRH-II and type II GnRH receptor genes in mammals</article-title>. <source>Neuroendocrinology</source>. <year>2009</year>;<volume>90</volume>(<issue>4</issue>):<fpage>416</fpage>–<lpage>432</lpage>.</citation>
</ref>
<ref id="bibr15-1933719112459244">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yahalom</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ben-Aroya</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>The gonadotropin-releasing hormone family of neuropeptides in the brain of human, bovine and rat: identification of a third isoform</article-title>. <source>FEBS Lett</source>. <year>1999</year>;<volume>463</volume>(<issue>3</issue>):<fpage>289</fpage>–<lpage>294</lpage>.</citation>
</ref>
<ref id="bibr16-1933719112459244">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Rosa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Celato</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Uccella</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Capella</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Detection of gonadotropin-releasing hormone receptor in normal human pituitary cells and pituitary adenomas using immunohistochemistry</article-title>. <source>Virchows Arch</source>. <year>2000</year>;<volume>437</volume>(<issue>3</issue>):<fpage>264</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr17-1933719112459244">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neill</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Duck</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Sellers</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Musgrove</surname>
<given-names>LC</given-names>
</name>
</person-group>. <article-title>A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2001</year>;<volume>282</volume>(<issue>4</issue>):<fpage>1012</fpage>–<lpage>1018</lpage>.</citation>
</ref>
<ref id="bibr18-1933719112459244">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borroni</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Di Blasio</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Gaffuri</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> <article-title>Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate</article-title>. <source>Mol Cell Endocrinol</source>. <year>2000</year>;<volume>159</volume>(<issue>1-2</issue>):<fpage>37</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr19-1933719112459244">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Auersperg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>PC</given-names>
</name>
</person-group>. <article-title>Type II gonadotropin-releasing hormone stimulates p38 mitogen-activated protein kinase and apoptosis in ovarian cancer cells</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2004</year>;<volume>89</volume>(<issue>6</issue>):<fpage>3020</fpage>–<lpage>3026</lpage>.</citation>
</ref>
<ref id="bibr20-1933719112459244">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Biljon</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wykes</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Krawetz</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Hapgood</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Type II gonadotropin-releasing hormone receptor transcripts in human sperm</article-title>. <source>Biol Reprod</source>. <year>2002</year>;<volume>67</volume>(<issue>6</issue>):<fpage>1741</fpage>–<lpage>1749</lpage>.</citation>
</ref>
<ref id="bibr21-1933719112459244">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ata</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Urman</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression?</article-title> <source>Reprod Biomed Online</source>. <year>2010</year>;<volume>20</volume>(<issue>1</issue>):<fpage>165</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr22-1933719112459244">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiesel</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Rody</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Greb</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Szilagyi</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Clinical use of GnRH analogues</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>2002</year>;<volume>56</volume>(<issue>6</issue>):<fpage>677</fpage>–<lpage>687</lpage>.</citation>
</ref>
<ref id="bibr23-1933719112459244">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shalev</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>PC</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone and reproductive medicine</article-title>. <source>J Obstet Gynaecol Can</source>. <year>2003</year>;<volume>25</volume>(<issue>2</issue>):<fpage>98</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr24-1933719112459244">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Bukulmez</surname>
<given-names>O</given-names>
</name>
</person-group>. <article-title>Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists</article-title>. <source>Curr Opin Obstet Gynecol</source>. <year>2011</year>;<volume>23</volume>(<issue>4</issue>):<fpage>238</fpage>–<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr25-1933719112459244">
<label>25</label>
<citation citation-type="web">
<collab collab-type="author">FDA DA</collab>. <comment>Abarelix (Praecis Pharmaceuticals / Schering AG’s Ple-naxis )</comment> <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov">http://www.accessdata.fda.gov</ext-link>. <year>2005</year>.</citation>
</ref>
<ref id="bibr26-1933719112459244">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Festuccia</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dondi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Piccolella</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors</article-title>. <source>Prostate</source>. <year>2010</year>;<volume>70</volume>(<issue>12</issue>):<fpage>1340</fpage>–<lpage>1349</lpage>.</citation>
</ref>
<ref id="bibr27-1933719112459244">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Naumann</surname>
<given-names>W.</given-names>
</name>
</person-group> <article-title>Fluorescence spectroscopic determination of the critical aggregation concentration of the GnRH antagonists Cetrorelix, Teverelix and Ozarelix</article-title>. <source>J Fluoresc</source>. <year>2010</year>;<volume>20</volume>(<issue>6</issue>):<fpage>1233</fpage>–<lpage>1240</lpage>.</citation>
</ref>
<ref id="bibr28-1933719112459244">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Struthers</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Nicholls</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Grundy</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2009</year>;<volume>94</volume>(<issue>2</issue>):<fpage>545</fpage>–<lpage>551</lpage>.</citation>
</ref>
<ref id="bibr29-1933719112459244">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group> <article-title>Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]be nzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor</article-title>. <source>J Med Chem</source>. <year>2008</year>;<volume>51</volume>(<issue>23</issue>):<fpage>7478</fpage>–<lpage>7485</lpage>.</citation>
</ref>
<ref id="bibr30-1933719112459244">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Metallinou</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Asimakopoulos</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schroer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nikolettos</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone in the ovary</article-title>. <source>Reprod Sci</source>. <year>2007</year>;<volume>14</volume>(<issue>8</issue>):<fpage>737</fpage>–<lpage>749</lpage>.</citation>
</ref>
<ref id="bibr31-1933719112459244">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Auersperg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>PC</given-names>
</name>
</person-group>. <article-title>Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid by gonadotropins in human immortalized ovarian surface epithelium and ovarian cancer cells</article-title>. <source>Endocr Relat Cancer</source>. <year>2006</year>;<volume>13</volume>(<issue>2</issue>):<fpage>641</fpage>–<lpage>651</lpage>.</citation>
</ref>
<ref id="bibr32-1933719112459244">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Oltmanns</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gurke</surname>
<given-names>EM</given-names>
</name>
<etal/>
</person-group> <article-title>Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells</article-title>. <source>Eur J Endocrinol</source>. <year>2001</year>;<volume>144</volume>(<issue>6</issue>):<fpage>677</fpage>–<lpage>685</lpage>.</citation>
</ref>
<ref id="bibr33-1933719112459244">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asimakopoulos</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nikolettos</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nehls</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Diedrich</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Al-Hasani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Metzen</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures</article-title>. <source>Fertil Steril</source>. <year>2006</year>;<volume>86</volume>(<issue>3</issue>):<fpage>636</fpage>–<lpage>641</lpage>.</citation>
</ref>
<ref id="bibr34-1933719112459244">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giampietro</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sancilio</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tiboni</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Rana</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Di Pietro</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Levels of apoptosis in human granulosa cells seem to be comparable after therapy with a gonadotropin-releasing hormone agonist or antagonist</article-title>. <source>Fertil Steril</source>. <year>2006</year>;<volume>85</volume>(<issue>2</issue>):<fpage>412</fpage>–<lpage>419</lpage>.</citation>
</ref>
<ref id="bibr35-1933719112459244">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Velasco</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Isaza</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Vidal</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix)</article-title>. <source>Hum Reprod</source>. <year>2001</year>;<volume>16</volume>(<issue>12</issue>):<fpage>2533</fpage>–<lpage>2539</lpage>.</citation>
</ref>
<ref id="bibr36-1933719112459244">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winkler</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bukulmez</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Carr</surname>
<given-names>BR</given-names>
</name>
</person-group>. <article-title>Gonadotropin releasing hormone antagonists suppress aromatase and anti-Mullerian hormone expression in human granulosa cells</article-title>. <source>Fertil Steril</source>. <year>2010</year>;<volume>94</volume>(<issue>5</issue>):<fpage>1832</fpage>–<lpage>1839</lpage>.</citation>
</ref>
<ref id="bibr37-1933719112459244">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone antagonists implications for oocyte quality and uterine receptivity</article-title>. <source>Ann N Y Acad Sci</source>. <year>2001l</year>;<volume>943</volume>:<fpage>49</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr38-1933719112459244">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horcajadas</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Minguez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dopazo</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Controlled ovarian stimulation induces a functional genomic delay of the endometrium with potential clinical implications</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2008</year>;<volume>93</volume>(<issue>11</issue>):<fpage>4500</fpage>–<lpage>4510</lpage>.</citation>
</ref>
<ref id="bibr39-1933719112459244">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>PC</given-names>
</name>
</person-group>. <article-title>Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans</article-title>. <source>Endocr Rev</source>. <year>2005</year>;<volume>26</volume>(<issue>2</issue>):<fpage>283</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr40-1933719112459244">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oehninger</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Revealing the enigmas of implantation: what is the true impact of ovarian hyperstimulation?</article-title> <source>Fertil Steril</source>. <year>2008</year>;<volume>89</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr41-1933719112459244">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Inany</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Abou-Setta</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Aboulghar</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review</article-title>. <source>Reprod Biomed Online</source>. <year>2007</year>;<volume>14</volume>(<issue>5</issue>):<fpage>640</fpage>–<lpage>649</lpage>.</citation>
</ref>
<ref id="bibr42-1933719112459244">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourgain</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Devroey</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>The endometrium in stimulated cycles for IVF</article-title>. <source>Hum Reprod Update</source>. <year>2003</year>;<volume>9</volume>(<issue>6</issue>):<fpage>515</fpage>–<lpage>522</lpage>.</citation>
</ref>
<ref id="bibr43-1933719112459244">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borthwick</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Charnock-Jones</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Tom</surname>
<given-names>BD</given-names>
</name>
<etal/>
</person-group> <article-title>Determination of the transcript profile of human endometrium</article-title>. <source>Mol Hum Reprod</source>. <year>2003</year>;<volume>9</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr44-1933719112459244">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bukulmez</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Rehman</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Langley</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Precycle administration of GnRH antagonist and microdose HCG decreases clinical pregnancy rates without affecting embryo quality and blastulation</article-title>. <source>Reprod Biomed Online</source>. <year>2006</year>;<volume>13</volume>(<issue>4</issue>):<fpage>465</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr45-1933719112459244">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bukulmez</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Carr</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Doody</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Doody</surname>
<given-names>KJ</given-names>
</name>
</person-group>. <article-title>Serum cetrorelix concentrations do not affect clinical pregnancy outcome in assisted reproduction</article-title>. <source>Fertil Steril</source>. <year>2008</year>;<volume>89</volume>(<issue>1</issue>):<fpage>74</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr46-1933719112459244">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haouzi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Assou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dechanet</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Controlled ovarian hyperstimulation for in vitro fertilization alters endometrial receptivity in humans: protocol effects</article-title>. <source>Biol Reprod</source>. <year>2010</year>;<volume>82</volume>(<issue>4</issue>):<fpage>679</fpage>–<lpage>686</lpage>.</citation>
</ref>
<ref id="bibr47-1933719112459244">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prapas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tavaniotou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Panagiotidis</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>GnRH antagonists and endometrial receptivity in oocyte recipients: a prospective randomized trial</article-title>. <source>Reprod Biomed Online</source>. <year>2009</year>;<volume>18</volume>(<issue>2</issue>):<fpage>276</fpage>–<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr48-1933719112459244">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Latre</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Clua</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Coroleu</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Replacing GnRH agonists with GnRH antagonists in oocyte recipient cycle did not adversely affect the pregnancy rates</article-title>. <source>Eur J Obstet Gynecol Reprod Biol</source>. <year>2011</year>;<volume>159</volume>(<issue>2</issue>):<fpage>355</fpage>–<lpage>358</lpage>.</citation>
</ref>
<ref id="bibr49-1933719112459244">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rackow</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Kliman</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>HS</given-names>
</name>
</person-group>. <article-title>GnRH antagonists may affect endometrial receptivity</article-title>. <source>Fertil Steril</source>. <year>2008</year>;<volume>89</volume>(<issue>5</issue>):<fpage>1234</fpage>–<lpage>1239</lpage>.</citation>
</ref>
<ref id="bibr50-1933719112459244">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Oberye</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bellver</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles</article-title>. <source>Hum Reprod</source>. <year>2005</year>;<volume>20</volume>(<issue>12</issue>):<fpage>3318</fpage>–<lpage>3327</lpage>.</citation>
</ref>
<ref id="bibr51-1933719112459244">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Vaerenbergh</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Van Lommel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ghislain</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group> <article-title>In GnRH antagonist/rec-FSH stimulated cycles, advanced endometrial maturation on the day of oocyte retrieval correlates with altered gene expression</article-title>. <source>Hum Reprod</source>. <year>2009</year>;<volume>24</volume>(<issue>5</issue>):<fpage>1085</fpage>–<lpage>1091</lpage>.</citation>
</ref>
<ref id="bibr52-1933719112459244">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albano</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Felberbaum</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Smitz</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group</article-title>. <source>Hum Reprod</source>. <year>2000</year>;<volume>15</volume>(<issue>3</issue>):<fpage>526</fpage>–<lpage>531</lpage>.</citation>
</ref>
<ref id="bibr53-1933719112459244">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borm</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mannaerts</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group</article-title>. <source>Hum Reprod</source>. <year>2000</year>;<volume>15</volume>(<issue>7</issue>):<fpage>1490</fpage>–<lpage>1498</lpage>.</citation>
</ref>
<ref id="bibr54-1933719112459244">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fluker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grifo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Leader</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation</article-title>. <source>Fertil Steril</source>. <year>2001</year>;<volume>75</volume>(<issue>1</issue>):<fpage>38</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr55-1933719112459244">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blumenfeld</surname>
<given-names>Z</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone antagonists instead of agonists: a change for the etter?</article-title> <source>Fertil Steril</source>. <year>2001</year>;<volume>76</volume>(<issue>3</issue>):<fpage>443</fpage>–<lpage>444</lpage>.</citation>
</ref>
<ref id="bibr56-1933719112459244">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolibianakis</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tarlatzis</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Devroey</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Diedrich</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Griesinger</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis</article-title>. <source>Hum Reprod Update</source>. <year>2006</year>;<volume>12</volume>(<issue>6</issue>):<fpage>651</fpage>–<lpage>671</lpage>.</citation>
</ref>
<ref id="bibr57-1933719112459244">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bodri</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sunkara</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Coomarasamy</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis</article-title>. <source>Fertil Steril</source>. <year>2011</year>;<volume>95</volume>(<issue>1</issue>):<fpage>164</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr58-1933719112459244">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Inany</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Youssef</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Aboulghar</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>GnRH antagonists are safer than agonists: an update of a Cochrane review</article-title>. <source>Hum Reprod Update</source>. <year>2011</year>;<volume>17</volume>(<issue>4</issue>):<fpage>435</fpage>.</citation>
</ref>
<ref id="bibr59-1933719112459244">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Yen</surname>
<given-names>SS</given-names>
</name>
</person-group>. <article-title>Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1995</year>;<volume>80</volume>(<issue>2</issue>):<fpage>580</fpage>–<lpage>585</lpage>.</citation>
</ref>
<ref id="bibr60-1933719112459244">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolfahrt</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kleine</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jarry</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rossmanith</surname>
<given-names>WG</given-names>
</name>
</person-group>. <article-title>Endogenous regulation of the GnRH receptor by GnRH in the human placenta</article-title>. <source>Mol Hum Reprod</source>. <year>2001</year>;<volume>7</volume>(<issue>1</issue>):<fpage>89</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr61-1933719112459244">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Norwitz</surname>
<given-names>ER</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone/gonadotropin-releasing hormone receptor signaling in the placenta</article-title>. <source>Curr Opin Endocrinol Diabetes Obes</source>. <year>2011</year>;<volume>18</volume>(<issue>6</issue>):<fpage>401</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr62-1933719112459244">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chou</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shalev</surname>
<given-names>E</given-names>
</name>
<name>
<surname>MacCalman</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>PC</given-names>
</name>
</person-group>. <article-title>The effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human extravillous cytotrophoblasts in vitro</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2002</year>;<volume>87</volume>(<issue>12</issue>):<fpage>5594</fpage>–<lpage>5603</lpage>.</citation>
</ref>
<ref id="bibr63-1933719112459244">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chou</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>MacCalman</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>PC</given-names>
</name>
</person-group>. <article-title>Regulatory effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the levels of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of metalloproteinases-1 in primary cultures of human extravillous cytotrophoblasts</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2003</year>;<volume>88</volume>(<issue>10</issue>):<fpage>4781</fpage>–<lpage>4790</lpage>.</citation>
</ref>
<ref id="bibr64-1933719112459244">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>YX</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>XQ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YL</given-names>
</name>
</person-group>. <article-title>GnRH I and II up-regulate MMP-26 expression through the JNK pathway in human cytotrophoblasts</article-title>. <source>Reprod Biol Endocrinol</source>. <year>2010</year>;<volume>8</volume>:<fpage>5</fpage>.</citation>
</ref>
<ref id="bibr65-1933719112459244">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casan</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Raga</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Polan</surname>
<given-names>ML</given-names>
</name>
</person-group>. <article-title>GnRH mRNA and protein expression in human preimplantation embryos</article-title>. <source>Mol Hum Reprod</source>. <year>1999</year>;<volume>5</volume>(<issue>3</issue>):<fpage>234</fpage>–<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr66-1933719112459244">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tug</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Uslu</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Cumbul</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of the gonadotropin-releasing hormone antagonist cetrorelix in the early postimplantation period on rat pregnancy</article-title>. <source>Eur J Obstet Gynecol Reprod Biol</source>. <year>2011</year>;<volume>155</volume>(<issue>2</issue>):<fpage>166</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr67-1933719112459244">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olivennes</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mannaerts</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Struijs</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bonduelle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Devroey</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report</article-title>. <source>Hum Reprod</source>. <year>2001</year>;<volume>16</volume>(<issue>8</issue>):<fpage>1588</fpage>–<lpage>1591</lpage>.</citation>
</ref>
<ref id="bibr68-1933719112459244">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boerrigter</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>de Bie</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Mannaerts</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>van Leeuwen</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Passier-Timmermans</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix</article-title>. <source>Hum Reprod</source>. <year>2002</year>;<volume>17</volume>(<issue>8</issue>):<fpage>2027</fpage>–<lpage>2034</lpage>.</citation>
</ref>
<ref id="bibr69-1933719112459244">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elizur</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Tulandi</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Drugs in infertility and fetal safety</article-title>. <source>Fertil Steril</source>. <year>2008</year>;<volume>89</volume>(<issue>6</issue>):<fpage>1595</fpage>–<lpage>1602</lpage>.</citation>
</ref>
<ref id="bibr70-1933719112459244">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonduelle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oberye</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mannaerts</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Devroey</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation</article-title>. <source>Hum Reprod</source>. <year>2010</year>;<volume>25</volume>(<issue>6</issue>):<fpage>1433</fpage>–<lpage>1440</lpage>.</citation>
</ref>
<ref id="bibr71-1933719112459244">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kyrou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Verpoest</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Staessen</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>No relationship between the type of pituitary suppression for IVF and chromosomal abnormality rates of blastomeres: an observational study</article-title>. <source>Fertil Steril</source>. <year>2011</year>;<volume>95</volume>(<issue>2</issue>):<fpage>563</fpage>–<lpage>567</lpage>.</citation>
</ref>
<ref id="bibr72-1933719112459244">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dondi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Festuccia</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Piccolella</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bologna</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Motta</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system</article-title>. <source>Oncol Rep</source>. <year>2006</year>;<volume>15</volume>(<issue>2</issue>):<fpage>393</fpage>–<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr73-1933719112459244">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maudsley</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pawson</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lopez de Maturana</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Millar</surname>
<given-names>RP</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor</article-title>. <source>Cancer Res</source>. <year>2004</year>;<volume>64</volume>(<issue>20</issue>):<fpage>7533</fpage>–<lpage>7544</lpage>.</citation>
</ref>
<ref id="bibr74-1933719112459244">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grundker</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schlotawa</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Viereck</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group> <article-title>Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor</article-title>. <source>Eur J Endocrinol</source>. <year>2004</year>;<volume>151</volume>:<fpage>141</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr75-1933719112459244">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emons</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Grundker</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gunthert</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Westphalen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kavanagh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Verschraegen</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>GnRH antagonists in the treatment of gynecological and breast cancers</article-title>. <source>Endocr Relat Cancer</source>. <year>2003</year>;<volume>10</volume>(<issue>2</issue>):<fpage>291</fpage>–<lpage>299</lpage>.</citation>
</ref>
<ref id="bibr76-1933719112459244">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>So</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>PC</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview</article-title>. <source>FEBS J</source>. <year>2008</year>;<volume>275</volume>(<issue>22</issue>):<fpage>5496</fpage>–<lpage>5511</lpage>.</citation>
</ref>
<ref id="bibr77-1933719112459244">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vincze</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Palyi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Daubner</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Antitumour effect of a gonadotropin-releasing-hormone antagonist (MI-1544) and its conjugate on human breast cancer cells and their xenografts</article-title>. <source>J Cancer Res Clin Oncol</source>. <year>1994</year>;<volume>120</volume>(<issue>10</issue>):<fpage>578</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr78-1933719112459244">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neves</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Ram</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Iyengar</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>G protein pathways</article-title>. <source>Science</source>. <year>2002</year>;<volume>296</volume>(<issue>5573</issue>):<fpage>1636</fpage>–<lpage>1639</lpage>.</citation>
</ref>
<ref id="bibr79-1933719112459244">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>White</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>ZL</given-names>
</name>
<name>
<surname>Millar</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Antiproliferative effects of GnRH agonists: prospects and problems for cancer therapy</article-title>. <source>Neuroendocrinology</source>. <year>2008</year>;<volume>88</volume>(<issue>2</issue>):<fpage>67</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr80-1933719112459244">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kakar</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Jennes</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues</article-title>. <source>Cancer Lett</source>. <year>1995</year>;<volume>98</volume>(<issue>1</issue>):<fpage>57</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr81-1933719112459244">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Yasojima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schwab</surname>
<given-names>C</given-names>
</name>
<name>
<surname>McGeer</surname>
<given-names>PL</given-names>
</name>
</person-group>. <article-title>Immunoidentification of gonadotropin releasing hormone receptor in human sperm, pituitary and cancer cells</article-title>. <source>Am J Reprod Immunol</source>. <year>2000</year>;<volume>44</volume>(<issue>3</issue>):<fpage>170</fpage>–<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr82-1933719112459244">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tandler</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kondruweit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fischlein</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Weyand</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Hormone therapy in men-increased risk of cardiac allograft rejection?</article-title> <source>J Heart Lung Transplant</source>. <year>2003</year>;<volume>22</volume>(<issue>7</issue>):<fpage>831</fpage>.</citation>
</ref>
<ref id="bibr83-1933719112459244">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>D'Amico</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Denham</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Crook</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions</article-title>. <source>J Clin Oncol</source>. <year>2007</year>;<volume>25</volume>(<issue>17</issue>):<fpage>2420</fpage>–<lpage>2425</lpage>.</citation>
</ref>
<ref id="bibr84-1933719112459244">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>D'Amico</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Sadetsky</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>PR</given-names>
</name>
</person-group>. <article-title>Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality</article-title>. <source>J Natl Cancer Inst</source>. <year>2007</year>;<volume>99</volume>(<issue>20</issue>):<fpage>1516</fpage>–<lpage>1524</lpage>.</citation>
</ref>
<ref id="bibr85-1933719112459244">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keating</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>O'Malley</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Freedland</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>MR</given-names>
</name>
</person-group>. <article-title>Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer</article-title>. <source>J Natl Cancer Inst</source>. <year>2010</year>;<volume>102</volume>(<issue>1</issue>):<fpage>39</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr86-1933719112459244">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Skinner</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The heart: a novel gonadotrophin-releasing hormone target</article-title>. <source>J Neuroendocrinol</source>. <year>2011</year>;<volume>23</volume>(<issue>5</issue>):<fpage>456</fpage>–<lpage>463</lpage>.</citation>
</ref>
<ref id="bibr87-1933719112459244">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Klotz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>van der Meulen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Colli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tanko</surname>
<given-names>LB</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix</article-title>. <source>J Urol</source>. <year>2011</year>;<volume>186</volume>(<issue>5</issue>):<fpage>1835</fpage>–<lpage>1842</lpage>.</citation>
</ref>
<ref id="bibr88-1933719112459244">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheung</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>AS</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues</article-title>. <source>FEBS J</source>. <year>2008</year>;<volume>275</volume>(<issue>22</issue>):<fpage>5479</fpage>–<lpage>5495</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>